January 31, 2017 11:07 AM ESTUpdated 03:19 PM
News Briefing

Pfiz­er prunes three drugs from its pipeline; Astel­las in-li­cens­es ear drug

Shehla Shakoor

Managing Director

• Pfiz­er’s lat­est pipeline up­date comes with a no­tice of three mid­night pro­gram ex­e­cu­tions. The phar­ma gi­ant has pruned three drugs from its sub­stan­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times